Cara Therapeutics EBITDA 2012-2024 | CARA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cara Therapeutics ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cara Therapeutics ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$119.5B
Regeneron Pharmaceuticals (REGN)	$114.6B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$101.6B
CSL (CSLLY)	$97.4B
GSK (GSK)	$84.8B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.4B
Biogen (BIIB)	$28.2B
BioNTech SE (BNTX)	$28B
Moderna (MRNA)	$24.6B
Illumina (ILMN)	$21.1B
BeiGene (BGNE)	$20.7B
Genmab (GMAB)	$16B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.6B
Incyte (INCY)	$12.5B
Insmed (INSM)	$12.5B
Vaxcyte (PCVX)	$12.4B
Bio-Techne Corp (TECH)	$12.4B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Ascendis Pharma (ASND)	$8.6B
Roivant Sciences (ROIV)	$8.6B
Legend Biotech (LEGN)	$8.5B
Repligen (RGEN)	$8.2B
Intra-Cellular Therapies (ITCI)	$7.7B
Exelixis (EXEL)	$7.5B